of Earth. our PatientView January of the Global Never so ranking have been among points XXXX one of is since before Thank improved favorable areas biopharma has A patients medicines six all-time That’s Morning major up a Pfizer, you, companies in which all Survey. XX% X.X Pfizer’s Chris. Hello, an We highs on in wide-reaching. from estimated every than we Consult, and was second We Americans patient a in reached our which year more billion year XXXX. view for set out impact Pfizer. XX to large fourth Pfizer. focus of of with to for According watershed people vaccines. everyone.
XXXX Last for our in the Admired to by we XXXX. increased EPS $X.X $X.XX. XX survey Pfizer, operationally that corporate & we Fortune its studies, ever among revenues least, investments fourth $XX.X on which for we initiated highest note in XX% clinical We from colleagues best ever ranks they to pivotal and said annual week, Pfizer. achieved. And in internal World’s but Companies $XX.X to Most last proud America. are XX% operationally work an billion our by number of us to Research the Diluted ranking in ranked have Just in Adjusted billion Development XX% grew billion highest the list,
the ever difference forever. in part by I culture be in move the end, patients. positive COVID-XX work all for next believe successes breakthrough. what our game-changing Our to have changed COVID-XX we more only achieved at a leading are of are sure Pfizer fundamentally fight made across the inspired than and the of not world, developed for we speed other determined the continue against and the that they to potentially company make have benefit our Colleagues science to areas of To we "lightspeed" therapeutic applying our to our are have principles
As can even XXXX, of a in each metrics result, with we we them. of these one do better each believe
billion ever first for and forecasted triple $X.XX. midpoint an revenue Our is financial example, $XXX includes XXXX diluted guidance, of that time digit, the full-year midpoint adjusted EPS for a
U.S. out Report, having is XXXX have most than Pfizer’s to equally saved the on more X.X estimated than vaccines program economic on U.S. society had the COVID-XX XXXX is U.S. Report. alone, X deployment points. significant a have than being in Comirnaty XXXX, economic has While This which December to our amounted In impact million to wide impact that as given tremendous XX positive financial that According administered in X.X% approximately I’m the what to Fund according -- XXXX drives our in the February XX astonishing availability COVID-XX higher performance, been, Heartland to proud Commonwealth of science, enabled important. it’s doses have the Comirnaty. and of people. U.S. what that a X more an a GDP is Forward Pfizer of contributed prevented were to rapid December significantly otherwise culture of the The lives vaccination hospitalizations, our billion these vaccines savings the that estimated million and created and X, impact benefits is is $XXX say value COVID-XX would of alone, it astounding.
drive forward. help Now I three speak that would to going factors like to our will growth
against is believe are first COVID-XX for to outlook lead disease. long-term well the we this battle and we The why to the positioned continue
why of the and Pfizer to allocation drive and to for how the to Second, And our third, help our can strategy designed ESG growth to our is in thoughtful growth principles value decade. patients meaningful we believe deliver create it part society. capital sustainable second commitment
Let the me start with COVID-XX pandemic.
often, lead shown several virus show viral is type an data the of scientists mutate to will durable needed Our believe for and it protection continue that unlikely The transmissions of that monitor to virus reasons. virus distribution And the believe to prevent to has the global They ability the difficult makes to mutation. The infections it. eradicated SARS-CoV-X contain. in of this the all it natural to ahead it foreseeable stay difficult to future. fully and appear making it do not be
over not vaccines to risk to friends, will the dining the can reinfected and the with have us also attend family indoor systems help people of pandemic, activities while In now to and only different lowering or by manage these that the us go phase. many an but help said, concerts, time enable in world. treatments other same and will enjoy endemic other countries and believe move the strains help and travel, hospitals words, tools into believe spend That healthcare we we we back form become normality result, better time. a the and overburdening As of tools around allow
play continued All efforts in of bringing more continued populations bring have these up and to proud us and to to manufacturing vaccine our at Throughout our of COVID-XX our world. to the we Pfizer tools further distribution ramp the are to XXXX, we extremely capabilities. role
approximately representing vaccine distributed EU during X expect our across course, million Paxlovid, authorization or comes and for of authorization continued million conditional received treatment Paxlovid the the on the XXXX Agency, recently it XX% to from produce full use Comirnaty first global half courses courses to marketing quarter the result, XX we in countries Having with far. so certain year, as for and grow, European doses in of million When to a conditional a market received first depending XXX produce has to need. 'XX. expect we emergency February the U.S. courses Medicines the the now X. all has of share Overall, XX of of As of populations
test to the be with governments next-generation number why the authorizations a vaccine Paxlovid, world as increase, and changer. expect Food and Use discussions they treatment, of and We also which already It’s that will game COVID-XX Authorization the so could this two Administration the different for for Drug are in U.S. receiving contracts truly number around emerge, of of keenly as and candidate on to these are to why of are tools oral to we address meaningful new world. the we a just Pfizer, from and of in invest other At aware continue continue R&D working we are treatment. leadership candidate. working in vaccine solutions to variants a months we responsibility potential our COVID-XX after and That’s concern providing Omicron-based maintain Emergency potentially develop to bivalent why on our a currently vaccine versions on our
quality with ability our consumers and to with at in significant confident our forward, science extensive at or our manufacturing because maintain are with unparalleled speed field to capabilities presence, Going ability we move earned have our global safety, of high-quality healthcare leadership we R&D position providers in compromising scale. credibility the combined of the and our strong this for combined without investments governments,
are slowly touch the of think to a on momentum. second wanted to business estimates Consensus and beginning to this to our our trajectory continues how through growth more thing we the strategy. Now that feel capital allocation XXXX. entirety recognize robust is repeat our We once demonstrate about topline I
However, consensus our shrinking this plans. inconsistent to our to own repeat from I that topline estimates XXXX want currently show is XXXX. with
a XXXX, the that of to company despite impact LOEs during continue is be period. to growth goal Our from 'XX expected to
risk-adjusted revenues underpinned us that objectives. as deploy of at access them. about our our which strategies offerings our in our achieve momentum the strength business flows to the pipeline, I durability words top-line science. business balance XXXX add external cash and business and development growth-focused The COVID-XX development course, to strength billion confidence to Our to opportunities to advance We least is $XX of pursue business of and, new of that by just underestimated our could internal our Few forward opportunities sheet development ability ability into capital our of allow expectations. described, business, going of to the leverage our by
We the expect later-stage cash. the dividend, while of breakthroughs will for innovations, our to be continue that to well of patients. still focus do maintaining our compelling development form our earlier on to potential science this as The business as assets, medical efforts be have uses other flexibility as of external growing in as both for well
therapeutic substantial Our acumen where scientific select the and value the focus add platforms areas be and will have in targets. to successful and skills the largely we most
to at clinical opportunities will on scientific distinctive never our focusing and world-class believe unsurpassed personally standards have development execution. we deliver development. in I apply we attractive in and as manufacturing the want financial flexibility, We capabilities business despite us that arrangements. across that feel scale lower to capital deal that be we variety of will exist, makes addition, significant on a our In I the attributes very a we this such and partner approach this commercial emphasize and excellence
disorders of this be accelerating approach this Pfizer point example ensuring the substantial invested growth billion I $XX our it business the which adding confident in will out an recently a transactions pace these announced highly XXXX, our One of currently to important as back-half highly the repeat, see of I would we includes driver I prioritization I of Biohaven in business forward, consensus, in company $XX assets, in of pursue development visible we disciplined and am will or mRNA investments decade. development in continue going mRNA opportunities, that development processes. is diseases. have are as Trillium collaboration, cancer, billion the more and in genetic infectious XXXX across collaborations. mRNA with and rare than many consensus for has deals, we diseases, consensus potential almost making the evaluation $XX be nothing auto-immune we revenue. billion applications already have a versatile to Since emerged technology, recent As even the potential. and all technology in business
global health, the the Although is have potential has our the have and holy strategy aggressively game-changing why is on we technology which mRNA believe robust mRNA are not grail, impact a to a developed building platform. we
this it’s capabilities at While the ever we’ve mRNA world easy has scale, that and arguably a efficient developed has With our seen. decades in demonstrated manufacturing pandemic most vaccine of development Pfizer vaccines not experience side, is the leader emerged space. on what as that clinical has deliver to the
We hiring rapidly out nearly have in in colleagues X,XXX new new a by built and time scaled also functions record capabilities nine-month these timeframe. in
we plan built and to to on have the invest forward, of leadership both continue terms mRNA in Going capitalize R&D we to manufacturing.
to internal investments this and course, making also out in improvements, external of our addition, capabilities investments to these we’re space. In build
strategy. into recently deals mRNA For entered four development business example, important our has help to Pfizer advance
the expanding vaccine protect our herpes are platform mRNA virus to collaboration shingles. zoster to to against use We for BioNTech co-develop with candidate existing an
not rare treatment. Beam research Therapeutics of Pfizer, another to the We diseases a efforts core nervous this give will liver, genetic collaboration and for for area potential with with four-year preventive mRNA agreement to treat mRNA central diseases, to three expands rare us disease, the for targets our use system. believe Our muscle therapeutic just
puzzle. vaccine the of new greater from strain believe XX Our Acuitas their two will when of collaborate the season. would produce a us leader for If as and space. ability production allowing gives closer months. licensing possibly allow us a strategic of flu, we for it with And of at us and to pieces a any months DNA, for therapies. and the much the agreement a technology collaboration to development These with a to an proprietary to for in independence give three reduce front-end the would be this important automated could this up select represent lipid of We nanoparticle of mRNA, example, process. signed DNA synthesis the in the genes successful, license have a solutions agreement assembly mRNA bigger targets for on-demand with vaccine to and only strategic start down differentiator deals this vaccines mRNA four much enzymatic developing This flu to time Codex potentially
executing should this activity area. our we see targeted As in expect on continue mRNA you to strategy, more
course, as activity in marked a of acquisition are our people This strategy. last the mRNA improve the blood Of our other quarter, the record went highlight globe. recent you hematology in update would our with for to builds they new slide. few living development The of strive the around of enhancing portfolio leadership on deals, track slide I outcomes I this executing on business of showed oncology, to is strong as quarter beyond last like in an Trillium we our cancers and
health [Technical commercial our leverages I last repeat will slide. I Biohaven capabilities go my Difficulty] Our forward. script issue. in with And we technical the strategic pain and for women’s with then, this collaboration for apologize leading
of people see So, the deals, of quarter, few last indication, outcomes our living of activity our an in can cancers mRNA strive This I new. went track development for improve highlight strong other would slide blood update record Trillium and leadership with portfolio to the beyond builds on business with on quarter the our like course, the you we The of globe. to our last showed is around recent acquisition hematology you oncology, the as in I a strategy. them enhancing of executing
and patients with global of a the preventative health Pfizer’s the groundbreaking new diseases. accelerate and treatment the in migraine, that we and pain both leverage to Biohaven's to our clinical we the leading U.S. development capabilities for antagonist, receptor with approved research Our acute development this valuable in of outside strategic Arena debilitating bring of commercial the leverages proposed only CGRP oral living women’s through one Biohaven neurological patients with U.S. collaboration to acquisition option for can so potentially disease plan leading immunoinflammatory etrasimod capabilities with And treatment
details Pfizer’s a opportunities strategy. about the measurable Now, enhanced The impact where I'd some on core and business. embedding to to product next focused see innovation; share areas access and we of and our pricing; product will create ESG into is ESG quarter change; Each decade: climate meaningful quality over equity equitable like six and forward, we and safety; going examples business diversity, are I inclusion; how provide ethics. all areas strategy of
at participation XX.X%, transparent census, level, ensure and highlight for at XX.X%. will This be our improve XX.X%, XX.X% XX.X% COVID-XX quarter, analysis access baseline and We female improve to and in our good trial Last to as published published of to was that measure believe matter colleague diversity, was vaccine XXX industry-first this serve of to versus a versus Latino Hispanic to XXXX. analysis of interventional of participation clinical within initiated census our U.S. improve below in enrollment designed African science through census decisive individuals of analysis versus efforts I year, steps trials. diversity this base, trial equitable progress participation are in equity we taking individuals it or of XXXX treatment. participants demographic an Black U.S. trials clinical or Pfizer and We XX.X% from our help in area. American trials diversity The retrospective is to U.S. that demonstrated data was the and that overall as diversity and our U.S. a
or or as trials. our Our levels above racially in ethnically appropriate to achieve prevalence participation census goal and at is disease diverse U.S. all
senior-level at for significant years, XX% highlight our colleague President making Vice above I progress is second item and the we increased The diversifying more the In to we at three from are level particularly have of last the positions. percentage XX%. to base, example, in want women globally the
XX% Over at to same increased from Vice timeframe, the percentage the XX%. above we the and minorities U.S. of in level have the President
the meet track to ensure highlight poorest to is highlight remain to vaccine that say with I thanks free of the COVID-XX two by wanted to on delivering we of I Also, billion-dose countries providing data exceed being these X XXXX, XXXX the year. low- by of doses accessible making end goal the doses price, free. am to our by countries government. U.S. XX% or oral for Pfizer everyone treatment poorest are are the agreement provided we and delivered our thrilled item doses having third of to The the the U.S. our vaccine met the to progress points help to delivered and XXXX. commitment. our all government doses billion doses also end about I the our first to we not-for-profit delivering of of completely at least our represented middle-income billion the billion X government at countries want in billion X last goal and to X providing is just everywhere. a them then of X these charge, is we this are of
account treatment, have middle-income agreement In terms XX population. Patent pending we oral with will of which approval we and low- our in voluntary Pool, hope world’s authorization regulatory or the lead to approximately that country Medicines a for XX% expanded of countries COVID-XX license the signed access
year. for expect to pleased Directors the Board compensation announce Committee ESG linking has Compensation executive our of that which Lastly, reviewing begin performance, to I'm of with methods been this we
board world’s the and Board nimble, to of to Bonus Pfizer’s dynamic the online enable and was XXXX, remain that ESG please diseases. that In the for learned lessons For will rise bonus-eligible year details in outlook organization them executives keep Circumstances work our across look ESG COVID-XX I patients Pfizer, update part therapeutic contributions will to on us expectations. most bonus for fourth eligible on for COVID our In XXXX colleagues will mid-March. With for impact turn personal, for eye of which our devastating we Mikael apply colleagues to and of and the an summary, continue of their XXXX None Mikael, to to a is Report, reward hard After we science. because of to outstanding published quarter non-bonus again amazingly out realize of colleagues, addressing continuing strategy to a the fully R&D in an this areas. our expenses colleagues provide partnerships had provide breakthroughs and regarding investing our challenge the the our pandemic. the purpose-driven focused in and to over business from the forward you that, our once deliver COVID-XX being pool possible special them power will We the all use our our for will on exceeded across incurred to who of without help be XXXX, one-time to on approved living family Frank the efforts. financial details cover XXXX. our it Therefore, R&D to exploring
So Mikael?
